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Abstract
Introduction The regulation of extracellular proteolytic activity
via the plasminogen activation system is complex, involving
numerous activators, inhibitors, and receptors. Previous studies
on monocytic and colon cell lines suggest that plasmin pre-
treatment can increase plasminogen binding, allowing the active
enzyme to generate binding sites for its precursor. Other studies
have shown the importance of pre-formed receptors such as
annexin II heterotetramer. However, few studies have used
techniques that exclusively characterise cell-surface events and
these mechanisms have not been investigated at the breast
cancer cell surface.
Methods We have studied plasminogen binding to MCF-7 in
which urokinase plasminogen activator receptor (uPAR) levels
were upregulated by PMA (12-O-tetradecanoylphorbol-13-
acetate) stimulation, allowing flexible and transient modulation of
cell-surface uPA. Similar experiments were also performed
using MDA-MB-231 cells, which overexpress uPAR/uPA
endogenously. Using techniques that preserve cell integrity, we
characterise the role of uPA as both a plasminogen receptor and
activator and quantify the relative contribution of pre-formed and
cryptic plasminogen receptors to plasminogen binding.
Results Cell-surface plasminogen binding was significantly
enhanced in the presence of elevated levels of uPA in an activity-
dependent manner and was greatly attenuated in the presence
of the plasmin inhibitor aprotinin. Pre-formed receptors were
also found to contribute to increased plasminogen binding after
PMA stimulation and to co-localise with uPA/uPAR and
plasminogen. Nevertheless, a relatively modest increase in
plasminogen-binding capacity coupled with an increase in uPA
led to a dramatic increase in the proteolytic capacity of these
cells.
Conclusion We show that the majority of lysine-dependent
plasminogen binding to breast cancer cells is ultimately
regulated by plasmin activity and is dependent on the presence
of significant levels of active uPA. The existence of a proteolytic
positive feedback loop in plasminogen activation has profound
implications for the ability of breast cancer cells expressing high
amounts of uPA to accumulate a large proteolytic capacity at the
cell surface, thereby conferring invasive potential.
Introduction
The components of the plasminogen activation system (PAS)
are important determinants of metastatic capacity, participat-
ing in both proteolytic and non-proteolytic pathways during
cancer progression [1,2]. Plasminogen (plg), the central
zymogen in the PAS, is secreted as a single-chain glyco-
sylated protein with an N-terminal glutamic acid (Glu) residue,
five kringle regions containing lysine-binding sites that regu-
late plg binding and activation (kringles 1, 4, and 5), and a C-
terminal protease domain [3]. Plg may be activated to the
broad-spectrum protease plasmin (pln) by a number of pro-
teases, including tissue-type plg activator (tPA), factor XIa,
factor XIIa, and kallikrein, via cleavage of the Arg561-Val562
peptide bond [4]. However, the urokinase plg activator (uPA)
is widely accepted as the most significant activator of plg dur-
ing tissue degradation [5,6]. This serine protease is secretedPage 1 of 11
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face bound to its GPI (glycosylphosphatidylinositol)-anchored
receptor, uPAR [5]. Receptor-bound pro-uPA is activated by
pln and a number of other proteases in vitro through cleavage
of the Lys158-Ile159 peptide bond to form the active two-chain
protease uPA. The uPA A-chain contains a growth factor-like
domain (amino acids 1 to 48) and a kringle domain (amino
acids 50 to 131), whereas the B-chain contains the protease
domain [7]. The reciprocal activation of pro-uPA by pln and of
plg by uPA is an important mechanism in the regulation of pln
activity [8].
Receptor-mediated cell-surface localisation of the various
components of the PAS (for example, uPA, plg, and plg activa-
tor inhibitor type 1 [PAI-1] and type 2 [PAI-2]) is critical for the
spatial and temporal regulation of proteolysis. Proteins, gan-
gliosides, and free fatty acids are among the mediators that
regulate cell-surface plg binding [9,10]. Several heterogene-
ous candidate receptors have been identified, including actin
[11], amphoterin [12], annexin II heterotetramer (AIIt) [13],
cytokeratin 8/18 [14], and α-enolase [15,16], with dissocia-
tion constant (Kd) values ranging from 0.1 to 2 μM. Receptor
candidates can be grouped into three classes: (a) those that
possess a pre-existing C-terminal lysine residue (pre-formed),
(b) those that are cleaved to expose a lysine residue (cryptic),
and (c) those that bind plg through a lysine-independent
mechanism [1]. Initial binding of Glu-plg to exposed internal or
C-terminal lysine residues results in a rapid conformational
change, whereas binding at a second lysine residue stabilises
the more open, activation-susceptible γ-conformation [17-19].
In addition, treatment of cells with basic caboxypeptidases sig-
nificantly reduces plg binding [20]. The lysine-dependent
binding of plg via cell-surface receptors therefore both
anchors plg to the cell surface and facilitates its activation to
pln. The high plg-binding capacity (104 to 107 binding sites per
cell) and relatively low affinity (Kd 0.1 to 2 μM) of cell-surface
plg binding suggest the presence of multiple plg receptors
that are responsible for the total plg-binding capacity of a cell
[1]. Furthermore, several studies have shown that limited pro-
teolysis of the cell surface with trypsin or pln to reveal C-termi-
nal lysyl residues results in enhanced plg binding in various
cell types [21-23]. Together, these observations point to a
general mechanism of cell-surface plg binding in which total
binding is determined by the collective expression of a spec-
trum of heterogeneous receptors and proteolytic activity.
Mounting evidence implicates uPA as a key regulator of breast
cancer metastasis and demonstrates a role for uPA in a
number of processes that facilitate tumour progression,
including extracellular matrix degradation, cell proliferation,
migration, and adhesion [24,25]. Furthermore, high levels of
uPA and its inhibitor PAI-1 in primary breast tumours are cor-
related with shortened disease-free interval and poor overall
survival, independent of other predictors such as tumour
grade, tumour size, and hormone receptor status [2,26]. Sig-
nificantly higher levels of uPA and uPAR are expressed at the
cell surface of metastatic breast cancer cells in vitro and these
cells are capable of binding larger amounts of Glu-plg at the
cell surface than non-metastatic breast cancer cells [27].
Moreover, although plg displays widespread cell-surface bind-
ing to a range of putative receptors, it is the uPA-co-localised
fraction of plg that is readily activated to pln [28]. This high-
lights uPA as an important regulator of cellular plg activation.
A direct, non-active-site interaction between the uPA A-chain
and plg has been shown to exist at the cell surface of the
monocytic cell line, U937 [29]. In addition, the amino-terminal
fragment of uPA (specifically the Lys135 residue) has been
shown to mediate the activation of plg by uPA and the recip-
rocal activation of pro-uPA by pln [30]. Thus, the accrual of
active uPA may be a key step in tumour invasion and metasta-
sis by controlling not only the levels of plg activated at the cell
surface but also the levels of plg bound. This mechanism has
not been definitively shown in situ (that is, at the cell surface)
on breast cancer cells. Using techniques that preserve cell
integrity and exclude the contribution of intracellular plg-bind-
ing moieties [28], we characterise the relative contribution of
uPA, pln, and several candidate plg receptors to cell-surface
plg binding on breast cancer cells.
Materials and methods
Specific proteins and antibodies
Active human urine-derived uPA (40% high molecular weight,
50% low molecular weight, 10% transitory forms; A-chain C-
terminal residue: Phe158) and mouse anti-cytokeratin 8/18
monoclonal antibody (mAb) (CBL195) were purchased from
Chemicon International (Temecula, CA, USA). Bovine apro-
tinin, rabbit anti-actin C-11 polyclonal antibody (pAb)
(A2066), rabbit immunoglobulin G (IgG) (I5006), goat IgG
(I9140), fluorescein isothiocyanate (FITC)-labelled goat anti-
mouse Fab-specific pAb (F4018), FITC-labelled rabbit anti-
goat pAb (F7367), FITC-labelled goat anti-rabbit pAb
(F6005), and cyanine (Cy) 3-labelled goat anti-mouse pAb
(C2181) were purchased from Sigma-Aldrich Pty. Ltd. (St.
Louis, MO, USA). Spectrozyme PL, mouse anti-uPAR mAb
(no. 3936), mouse anti-uPA A-chain mAb (no. 3921), and
mouse anti-uPA B-chain mAb (no. 394) were purchased from
American Diagnostica Inc. (Stamford, CT, USA). Goat anti-
S100A10 (p11) mAb (AF1698) was purchased from R&D
Systems, Inc. (Minneapolis, MN, USA). Human α2-antiplasmin
was purchased from Molecular Innovations, Inc. (Southfield,
MI, USA). Goat anti-annexin II (C-16) pAb (sc-1924) was pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). Irrelevant isotype-matched control antibodies mouse
anti-sheep lymphocyte antigen IgG1 mAb (SBU-T6) and IgG2α
mAb (SBU-LCA) were obtained from the Centre for Animal
Biotechnology (Parkville, Victoria, Australia).Page 2 of 11
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MCF-7 (low uPAR/uPA-expressing, low plg-binding) and
MDA-MB-231 (high uPAR/uPA-expressing, high plg-binding)
cell lines were maintained in RPMI-1640 medium (Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with 5%
heat-inactivated foetal calf serum (FCS) (Thermo Electron
Corporation, Waltham, MA, USA) at 37°C in a humidified incu-
bator with 5% CO2.
Purification and modification of Glu-plg
Human Glu-plg was affinity-purified from plasma using Lysine
Sepharose™ 4B (GE Healthcare, Little Chalfont, Buckingham-
shire, UK) as described [16]. Glu-plg was either FITC- or Cy5-
conjugated as described [28,31].
Inactivation of uPA
Purified human uPA (0.5 mg/ml) was inactivated by incubation
overnight with alpha-toluenesulfonyl fluoride (PMSF) (1 mM) in
phosphate-buffered saline (PBS) (pH 7.4) at 4°C (final con-
centration of isopropanol 2%). PMSF inactivation of uPA was
maintained for the duration of the assays (data not shown). Pln
activity assays confirmed that residual excess PMSF in the
preparation was negligible after overnight incubation and dilu-
tion for use in the assays (data not shown).
PMA treatment to enhance cell-surface uPA
MCF-7 cells were cultured for 32 hours in 5% FCS/RPMI-
1640 and then incubated with PMA (12-O-tetradecanoylphor-
bol-13-acetate) (100 nM; concentration of ethanol 0.006%
vol/vol) without change of media at 37°C for a further 16 hours
as previously described [32]. Control cells were treated with
an equivalent volume of ethanol in 5% FCS/RPMI-1640. Cells
were characterised for plg binding and activation and PAS
component expression as described below. Ethanol has been
shown to increase uPAR expression in certain cell types [33],
but this effect was not observed in MCF-7 at the low concen-
tration used (data not shown).
Cell-surface plg binding assays
Throughout this study, only the lysine-dependent proportion of
total plg binding is shown because this represents the pool of
cell-bound plg which is readily activatable [28]. Subconfluent,
adherent cells were prepared and analysed for lysine-depend-
ent plg binding essentially as described [27]. However, prior
to incubation with antibodies or plg, cells were pre-incubated
with either uPA or PMSF-inactivated uPA (PMSF-uPA) (50
nM) in binding buffer (Hanks' balanced salt solution containing
1 mM calcium chloride, 1 mM magnesium chloride, 20 mM
HEPES [N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic
acid)], and 0.1% bovine serum albumin) (pH 7.4) for 10 min-
utes at room temperature (21°C to 25°C) (allowing limited pro-
teolytic activity) and then washed prior to further analysis on
ice with all incubations performed in the absence or presence
of aprotinin (1.6 trypsin inhibitor units [TIU]). Lysine-depend-
ent plg binding was calculated as total plg binding minus bind-
ing in the presence of 1 mM tranexamic acid. Lysine-
dependent binding was typically 58% ± 3% of total cell-sur-
face binding in the MCF-7 cell line and 83% ± 1% in the MDA-
MB-231 cell line. For antibody inhibition experiments, cells
were pre-incubated for 30 minutes with 20 μg/ml anti-uPA A-
chain (mAb no. 3921), anti-uPA B-chain (mAb no. 394), or an
irrelevant isotype control on ice prior to the plg binding step.
Cells were then washed and analysed for cell-surface lysine-
dependent plg binding as described [27].
Plg binding assays were performed using dual-colour flow
cytometry with propidium iodide (PI) to distinguish between
viable and non-viable cells as previously described [27]. Only
cells that excluded PI (that is, viable cells with intact mem-
branes) were included in further analyses. Cell-surface-associ-
ated fluorescence was measured on an LSR II flow cytometer
(BD Biosciences, San Jose, CA, USA). All data were analysed
using WinMDI version 2.8 (The Scripps Research Institute, La
Jolla, CA, USA) [34].
Plg activation assays
MCF-7 cells were grown, PMA-treated, and pre-incubated
with uPA or PMSF-uPA (50 nM) for 10 minutes at room tem-
perature as per plg binding assays in modified (no phenol red)
binding buffer (MBB) (pH 7.4). Cells were then washed twice
and resuspended in MBB containing 0.5 μM Glu-plg in the
presence and absence of 1.6 TIU aprotinin (to measure pln-
dependent effects). Cells were incubated for 10 minutes at
room temperature before addition of 0.4 μM of the colorimetric
pln substrate Spectrozyme PL. Plg activation assays were per-
formed in the presence of 0.25 μM α2-antiplasmin to inhibit pln
activity in solution and to ensure that only cell-surface pln activ-
ity was assayed. Pln activity was measured at 405 nm at 37°C
using a Spectramax 250 plate reader with Softmax Pro version
4.0 software (Molecular Devices Corporation, Sunnyvale, CA,
USA).
Cell-surface pre-formed receptor characterisation by 
flow cytometry and confocal microscopy
Cell-surface uPAR, uPA, cytokeratin 8/18, actin, annexin II,
and S100A10 (p11) expression was analysed by indirect
immunofluorescence staining as previously described [27].
Only cells that excluded PI (that is, viable cells with intact
membranes) were included in further analyses. Isotype control
fluorescence was subtracted from all measurements. These
antibodies have previously been shown to detect their respec-
tive antigens on positive controls [28].
For confocal microscopy, MCF7 cells (2 × 105 cells per millili-
tre) were cultured onto sterile glass coverslips in 24-well tis-
sue culture plates in 1 ml of 5% FCS/RPMI-1640 for 32 hours
and PMA treated as above. Coverslips were washed twice
with ice-cold MBB and fixed by incubation with freshly pre-
pared, ice-cold 3.75% paraformaldehyde in PBS (pH 7.4) for
15 minutes on ice. Coverslips were washed twice and blockedPage 3 of 11
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10 minutes at room temperature with MBB containing 50 nM
uPA. Cells were washed and incubated for 45 minutes with
Cy5-labelled Glu-plg (0.5 μM) in the presence and absence of
5 mM tranexamic acid in MBB on ice in the absence of light.
Cells were washed and incubated for 30 minutes with 10 to
20 μg/ml mouse anti-uPAR mAb (no. 3936), mouse anti-uPA
mAb (no. 394), or goat anti-annexin II (C-16) pAb (sc-1924) in
MBB on ice in the absence of light. After two washes, samples
were incubated for 30 minutes either with 1:50 FITC- or Cy3-
labelled goat anti-mouse pAb or with FITC-labelled rabbit anti-
goat pAb in MBB on ice in the absence of light and washed
three times with ice-cold MBB. Samples were mounted and
examined as previously described [28] using a × 40/1.00
FLUOTAR PL oil immersion objective lens on a Leica DM IRBE
confocal microscope (Leica Microsystems GmbH, Wetzlar,
Germany). All images were analysed using Confocal Assistant
version 4.02 (Todd Clark Brelje, University of Minnesota, Min-
neapolis, MN, USA).
Statistics
Graphs shown represent mean ± standard error (performed in
duplicate) and are representative of experiments performed on
multiple days. The means of the data were compared statisti-
cally using Student's t test (assuming equal variances). Where
variances differed significantly, data were log-transformed
prior to analysis by t test.
Results
Plg binds directly to endogenous (pro)-uPA
The presence of a non-active site, direct binding determinant
for plg in the C-terminal region (Gly149-Lys158) of the uPA A-
chain has been shown to exist on U937, a monocytic cell line
[29], and we have previously shown that uPA and plg co-local-
ise at the surface of breast cancer cells [28]. To determine
whether this interaction occurs at the surface of MDA-MB-231
cells (a breast cancer cell line that has high endogenous uPA
expression [27]), binding experiments using antibodies
directed against the A- or B-chain of uPA were performed
under conditions that predominantly exclude proteolytic acti-
vation of plg by uPA. A significant decrease (34%) in cell-sur-
face lysine-dependent plg binding was observed only in the
presence of anti-uPA A-chain mAb (Figure 1), indicating the
presence of a plg-binding site within this domain of uPA. To
confirm that the A-chain uPA antibody used did not dissociate
bound uPA, thus leading to the observed decrease in plg bind-
ing, we performed these blocking experiments using stimu-
lated MCF-7 cells with significant levels of cell-surface urine-
derived uPA, which lacks the C-terminal lysine (see below).
Under these conditions, plg binding was not decreased (data
not shown), which also confirms the importance of the C-ter-
minal lysine for binding. Interestingly, under similar conditions,
uPAR-transfected T-47D cells [35], which display concomi-
tant but small and variable increases in endogenous uPA (1.7
± 0.23-fold), also displayed small but variable increases in plg-
binding capacity (1.7 ± 0.19-fold).
Modulation of cell-surface uPA on MCF-7 cells
High levels of uPA on breast cancer cell lines are linked to
increased plg binding [27,28]. We and others [36] have found
that acid stripping of the cell surface to remove uPA markedly
compromises membrane integrity, making cell-surface meas-
urements difficult and increasing the likelihood of introducing
artifacts. In addition, upregulation of uPAR using transfection
techniques [35] did not allow sufficient control of uPA levels
between experiments (data not shown). Therefore, to directly
assess the effect of altered cell-surface uPA on plg-binding
capacity, we used a model breast cancer cell line (MCF-7) that
has very low constitutive cell-surface uPAR and modulated its
expression by PMA stimulation [32]. After 16 hours of stimula-
tion with 100 nM PMA, a large enhancement (approximately
12-fold; mean fluorescence intensity [MFI] of 3.4 ± 1.2 versus
41.4 ± 4.2 fluorescence units after PMA stimulation) of cell-
surface uPAR was observed on MCF-7 cells (Figure 2a,b).
Enhancement of uPAR expression was observed without sig-
nificant changes to endogenous cell-surface expression of
Figure 1
Cell-surface plasminogen (plg) binding via (pro)-uPA on MDA-MB-231 cel s
cells. MDA-MB-231 cells were detached, washed, and pre-incubated 
on ice for 30 minutes with antibodies against the uPA A-chain, the uPA 
B-chain, or an irrelevant isotype control antibody. Cells were then 
washed and incubated for 45 minutes on ice in the dark with fluores-
cein isothiocyanate-labelled Glu-plg in the absence (total binding) and 
presence (lysine-independent binding) of 1 mM tranexamic acid. Cells 
were then washed and analysed for cell-surface plg binding in the pres-
ence of 5 μg/ml of the vital stain, propidium iodide, using dual-colour 
flow cytometry. Lysine-dependent plg binding was calculated by sub-
tracting lysine-independent binding from total binding. Glu, glutamic 
acid; uPA, urokinase plasminogen activator.Page 4 of 11
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which had low to non-detectable expression. Neither PAI-1
nor PAI-2 was detectable at significant levels at the cell sur-
face under any condition (data not shown). Increases in
endogenous uPA after PMA stimulation were small (twofold;
MFI of 6.19 ± 2.07 versus 14.2 ± 6.0 fluorescence units after
PMA stimulation) but not statistically significant. Although the
increase in annexin II (1.4-fold) was also relatively small, this
observation is significant because basal annexin II expression
was high (MFI of 782 ± 5 versus 895 ± 17 after PMA stimula-
tion). Interestingly, a substantial (6.1-fold) increase in
S100A10 (p11) expression was also observed after PMA
stimulation (Figure 2a). However, it should be noted that over-
all expression levels of p11 were still low (MFI of 1.74 ± 0.26
versus 10.73 ± 1.04 fluorescence units after PMA
stimulation).
Dose-dependent cell-surface binding of exogenous uPA was
observed on PMA-stimulated MCF-7 cells. Saturation of
enhanced uPAR was observed at 50 nM uPA (Figure 3), rep-
resenting an approximately eightfold increase in cell-surface
uPA compared to untreated controls. PMSF-uPA displayed
identical cell-surface binding properties to active uPA (Figure
3), indicating that inactivation did not affect the binding char-
acteristics of uPA. Several studies have suggested that uPA
may cleave cell-surface uPAR, rendering it incapable of bind-
ing uPA and its other binding partners [37-39]. However, we
observed no change in the level of cell-surface uPAR subse-
quent to incubation with uPA (data not shown). Thus, stimula-
tion of MCF-7 cells with PMA for 16 hours followed by
incubation with 50 nM uPA provides appropriate flexibility in
transient modulation of cell-surface uPA. Furthermore, the use
of urine-derived uPA eliminates significant A-chain Lys158 res-
idue contribution to plg binding and thus this model is highly
useful for investigating the role of uPA activity in cell-surface
plg binding and activation.
Figure 2
Plasminogen activation system component changes on PMA-treated MCF-7 cells
MCF-7 cells. MCF-7 cells were cultured for 16 hours in 5% foetal calf 
serum/RPMI containing 100 nM PMA. (a) Cells were washed and incu-
bated for 30 minutes on ice with 10 to 20 μg/ml of anti-uPAR mono-
clonal antibody (mAb), anti-uPA mAb, anti-tPA mAb, anti-annexin II (Ann 
II) C-16 polyclonal antibody (pAb), anti-S100A10 (p11) pAb, or a 
matched isotype control antibody. Cells were then washed and incu-
bated for 45 minutes on ice in the dark with a 1:200 dilution of appro-
priate secondary antibody labelled with fluorescein isothiocyanate 
(FITC). All cells were then washed and analysed for cell-surface-associ-
ated FITC fluorescence in the presence of 5 μg/ml propidium iodide 
using dual-colour flow cytometry. Specific antibody binding was calcu-
lated by subtracting control antibody fluorescence. Solid line indicates 
a fold increase of 1 (equivalent to no change). P values indicate a sig-
nificant increase compared to the corresponding untreated control. (b) 
Confocal microscopy on attached cells was also used to verify 
enhancement of cell-surface uPAR by PMA treatment. PMA, 12-O-tet-
radecanoylphorbol 13-acetate; tPA, tissue-type plasminogen activator; 
uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen 
activator receptor.
Figure 3
Cell-surface urokinase plasminogen activator (uPA) binding on PMA-
stimulated cells. MCF-7 cells were cultured for 16 hours in 5% foetal 
calf serum/RPMI containing 100 nM PMA (open symbols) or vehicle 
control (closed symbols). Cells were detached, washed, and pre-incu-
bated for 30 minutes on ice with increasing concentrations of active 
uPA or PMSF-inactivated uPA. Cells were then washed and analysed 
for cell-surface uPA level as in Figure 2. Curves were fitted using a one-
site binding equation in GraphPad Prism version 4.00 (GraphPad Soft-
ware, Inc., San Diego, CA, USA). MFI, mean fluorescence intensity; 
PMA, 12-O-tetradecanoylphorbol 13-acetate; PMSF, alpha-toluenesul-
fonyl fluoride.Page 5 of 11
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putative plg receptors
To investigate the spatial relationship between cell-surface-
bound plg and putative plg receptors, we performed co-local-
isation experiments using immunofluorescence staining and
confocal microscopy. Results for both control and PMA-stim-
ulated MCF-7 cells pre-incubated with exogenous uPA are
shown (Figure 4). In the absence of exogenous uPA, regard-
less of PMA stimulation, very little uPA staining was observed
(data not shown).
In MCF-7 cells, annexin II displays punctuate cell-surface and
diffuse intracellular staining. After PMA stimulation, there was
both a subtle increase and a distinct redistribution of cell-sur-
face annexin II into clustered surface puncta (Figure 4). A sim-
ilar localisation pattern was observed for exogenous uPA in
response to PMA stimulation, reflecting the large increase in
uPAR expression compared to control cells (Figure 4). After
PMA stimulation, there also appeared to be a visible increase
in cell-surface-bound plg, which was subtle and concentrated
in specific regions (Figure 4). Plg binding was lysine-depend-
ent given that binding was significantly decreased in the pres-
ence of tranexamic acid (Figure 4, inset). Importantly, clear co-
localisation of uPA, annexin II, and plg was observed at the sur-
face of these cells after PMA stimulation and exogenous uPA
treatment (Figure 4). Very little co-localisation was observed in
uPA-treated unstimulated control cells. Because urine-derived
uPA was used, these data indirectly show that uPA, annexin II,
and plg can co-localise independently of an uPA A-chain/plg
interaction after PMA stimulation.
uPA proteolytic capacity is the critical determinant of plg 
binding and activation
Several studies in other cell types have shown that limited pro-
teolysis of the cell surface by pln can reveal cryptic plg-binding
sites [21,22,40]. To assess the effect of cell-surface proteo-
lytic activity on plg binding, a number of experiments were per-
formed on MCF-7 cells with modulated active and inactive
exogenous uPA levels. No significant difference in lysine-
dependent plg binding was observed in control cells pre-incu-
bated with either uPA or PMSF-uPA (data not shown). How-
ever, lysine-dependent plg binding on MCF-7 cells after PMA
stimulation increased to approximately 183% compared to
control cells (Figure 5a). Subsequent addition of exogenous
uPA caused a further approximately 37% increase in plg bind-
ing, which was not observed with the addition of PMSF-uPA
(Figure 5a). Given that the direct, non-active-site-dependent
interaction of plg with uPA was precluded through the use of
urine-derived uPA, this clearly demonstrates that the additional
plg binding observed after uPA treatment of PMA-stimulated
cells is entirely dependent on uPA catalytic activity. This effect
is functionally important because PMA stimulation alone
(which increased plg binding) had no effect on plg activation,
whereas uPA treatment of these cells caused a very large (15-
fold) increase in cell-surface pln generation (Figure 5b). In
addition, the pln generated represents activated cell-surface-
bound plg as solution-phase pln was inhibited by the presence
of α2-antiplasmin. Hence, without uPA catalytic activity at the
cell surface, increased plg binding alone is not sufficient for
increased plg activation. Nevertheless, increased lysine-
dependent plg binding has been clearly linked to increased
plg activation in the presence of uPA activity [27].
To further dissect lysine-dependent plg binding mechanisms
in our experimental model, experiments were performed in the
presence of the pln inhibitor aprotinin to allow a distinction to
be made between pln-dependent binding (total binding minus
binding in the presence of aprotinin) and pln-independent
binding (residual binding in the presence of aprotinin). Plg
binding on control (unstimulated) cells, regardless of uPA
treatment, was entirely pln-dependent as very little residual plg
binding was observed in the presence of aprotinin (Figure 5c).
In contrast, PMA stimulation caused an increase in plg bind-
ing, which appears to be due to a corresponding increase in
pln-independent binding (denoted by the hatched bars in Fig-
ure 5c). This pln-independent increase in plg binding may be
due to the de novo expression of plg-binding moieties after
PMA stimulation. Furthermore, amongst the PMA-stimulated
cells, the additional and significant increase in plg binding
observed after exogenous active uPA treatment was entirely
pln-dependent given that there was no corresponding
increase in residual plg binding in the presence of aprotinin
(Figure 5c). A similar binding relationship was observed on
Figure 4
Cell-surface urokinase plasminogen activator (uPA) binding on PMA-PMA stimulation prior to urok as  pl smin gen activator (uPA) incuba-
tion mediates increased plasminogen (plg) binding at the MCF-7 cell 
surface. Confocal microscopy images of control and PMA-stimulated 
(100 nM, 16 hours) MCF-7 cells both incubated with 50 nM uPA for 10 
minutes at room temperature, washed, and probed for annexin II (AnnII), 
uPA, and Glu-plg binding. Areas of co-localisation of annexin II, uPA, 
and Glu-plg are shown in white in the merged image. Arrows indicate 
areas of concentrated expression. Inset shows non-lysine-dependent 
plg binding (that is, plg binding in the presence of 5 mM tranexamic 
acid). Glu, glutamic acid; PAS, plasminogen activation system; PMA, 
12-O-tetradecanoylphorbol 13-acetate.Page 6 of 11
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capacity for plg and uPA binding and activation [27]), where
pln-dependent binding accounted for approximately 64% and
pln-independent binding for 36% of the total lysine-dependent
plg binding. Taken together, these data indicate the impor-
tance of increased uPA proteolytic capacity for increased cell-
surface plg binding and activation but also suggest a role for
pre-formed receptors.
Discussion
A number of clinical and functional studies have shown that
uPA-mediated plg activation is integral to the processes of
cancer cell invasion and metastasis [1,2,6]. We have used
techniques that maintain cell viability (and hence exclude intra-
cellular plg binding from the analyses) to confirm that the
majority of plg binding on breast cancer cells is regulated by
pln activity at the cell surface. We show that regardless of the
level of plg bound, active uPA must be present at significant
Figure 5
Plasminogen binding and activation on MCF-7 cells. After culture for 16 hours in 5% foetal calf serum/RPMI containing 100 nM PMA (PMA-stimu-
lated) or vehicle alone (control), cells were detached and pre-incubated for 10 minutes at room temperature in the absence or presence of 50 nM 
active urokinase plasminogen activator (uPA) or PMSF-inactivated uPA (PMSF-uPA), washed, and then analysed for cell-surface plg binding or acti-
vation. (a) Cell-surface, lysine-dependent plg binding to PMA-stimulated MCF-7 cells is shown as a percentage increase compared to unstimulated 
MCF-7 cells in the absence of uPA. (b) Cell-surface plasmin (pln) generation. Pln activity assays were performed using Spectrozyme PL in the pres-
ence of α2-antiplasmin to inhibit any solution-phase pln generation. Activity in the presence of aprotinin (pln inhibitor) was also measured and sub-
tracted from all values to determine pln-dependent activity. (c) Cell-surface lysine-dependent fluorescein isothiocyanate-plg binding was measured 
in the presence or absence of aprotinin. Percentages show the proportion of binding due to pln activity at the cell surface (that is, pln-dependent 
binding calculated as total binding minus binding in the presence of aprotinin; open bars) and the proportion that is independent of pln activity (that 
is, pln-independent binding calculated as residual binding in the presence of aprotinin; hatched bars), which together constitute total lysine-depend-
ent plg binding. *Significant increase compared to unstimulated control cells not pre-incubated with uPA or PMSF-uPA (p < 0.05). **Significant 
increase compared to PMA-stimulated cells not pre-incubated with uPA or PMSF-uPA. MFI, mean fluorescence intensity; PMA, 12-O-tetradecanoyl-
phorbol-13-acetate; PMSF, alpha-toluenesulfonyl fluoride.Page 7 of 11
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confirm that a proportion of plg binding to the cell surface is
mediated via a region in the endogenous (pro)-uPA A-chain.
Furthermore, we demonstrate that annexin II is present at high
levels on the surface of MCF-7 cells and co-localises with plg
and uPA/uPAR under conditions of increased cell-surface plg
binding.
Progression to the metastatic phenotype is clearly associated
with deregulation of the uPA system [1,24,41,42], which also
appears to be coupled with an increase in pre-formed plg
receptors [28]. Plg bound at the cell surface may then be acti-
vated to pln by cell-surface or possibly stromal cell-derived
[43-46] uPA. The increased uPA expression associated with
metastatic cancer increases pln activity, catalysing extracellu-
lar matrix degradation and promoting migration [47]. We have
previously shown that metastatic breast cancer cells (for
example, MDA-MB-231) have increased uPA at the cell sur-
face and have the potential to bind and activate relatively large
amounts of plg compared to nonmetastatic cells (for example,
MCF-7 and T-47D) [27]. In a clinical setting, strong immuno-
histochemical staining of uPA has been significantly correlated
to more invasive tumours [48,49] and uPA constitutes a
strong, statistically significant independent prognostic marker
for shorter disease-free survival [50-52]. Together, these
results suggest that uPA has a key role in regulating metastatic
potential by modulating cell-surface plg binding and activating
capacity and hence proteolytic activity.
Pro-uPA, though termed an 'inactive' precursor, has been
shown to possess some minimal intrinsic plg activating capa-
bility [53]. In a proposed model based on studies of monocytic
and colon cancer cell lines, cells with significant amounts of
pro-uPA at the cell surface are able to activate bound plg, the
pln formed then exposes lysine residues through limited prote-
olysis of nearby proteins and in addition activates pro-uPA to
the more efficient uPA [40,54]. The newly bound plg is then
activated, creating a positive feedback activation loop
between (pro)-uPA and plg/pln which has the potential to gen-
erate large amounts of pln at the cell surface. Our results
provide further support for this mechanism of action on breast
cancer cells. MCF-7 cells possess low endogenous cell-sur-
face (pro)-uPA levels and bind small amounts of cell-surface
plg [27]. As a result, they possess comparatively little plg acti-
vating ability and display only minimal invasive activity [27]. By
enhancing uPAR levels and using urine-derived uPA to
preclude direct lysine-dependent binding, we clearly confirm
that plg binding is largely dependent on uPA activity and sub-
sequent pln activity and that pln does play a key role in the gen-
eration of new plg-binding sites at the cell surface (Figure 5).
The ability of pln to generate its own plg-binding sites in a pos-
itive feedback loop (independent of de novo synthesis) has
been demonstrated on neutrophils and monocytic and colon
cancer cell lines by pretreatment of cells with pln [21-23].
Additionally, carboxypeptidase treatment to remove C-terminal
lysine residues from proteins has been shown to cause
marked decreases in plg binding in a number of cell types
[20,22,55]. In our experience, however, pre-treatment with
high concentrations of pln at 37°C devastates cell viability in
vitro. Moreover, we have previously shown that non-viable cell
populations bind approximately 100 times more plg, masking
changes in cell-surface binding on viable cells [27]. Thus, the
use of 125I-plg (which cannot distinguish between intracellular
and cell-surface binding) to measure cell-surface plg binding
is unsuitable because considerable artifactual contributions of
intracellular plg binding cannot be excluded. In contrast, the
use of dual-colour flow cytometry is far superior because it
allows clear distinction of cell-surface from intracellular plg
binding by exclusion of non-viable cells. Furthermore, the use
of aprotinin in this study to quantify the contribution of pln
activity to plg binding removes the inherent complicating effect
of pln treatment on cell viability. These modifications therefore
represent significant improvements to previous works and
allow careful characterisation of cell-surface events.
A number of proteins, including actin, AIIt (consisting of two
molecules of annexin II [p36 subunit] and two molecules of
S100A10 [p11 subunit]), cytokeratin 8, and α-enolase, have
been shown to both bind and enhance the activation of plg to
pln on a number of cell types [1]. The nature of cell-surface plg
binding and activation (that is, low-affinity, lysine-dependent)
suggests a general requirement for exposed lysine residues at
the cell surface rather than the presence of a specific receptor
or suite of receptors to promote plg binding and activation.
We did not observe significant expression of actin or cytoker-
atin 8/18 at the MCF-7 cell surface under any condition. How-
ever, MCF-7 cells have relatively high endogenous levels of
annexin II at the cell surface (Figures 2 and 4). Annexin II has
been shown to exist in monomeric, heterodimeric, and heter-
otetrameric forms [56] and associates with the cell surface in
a calcium-dependent manner [57]. Initially, it was reported that
annexin II on endothelial cells bound tPA, plg, and pln [58],
suggesting that although native annexin II does not contain a
C-terminal lysine residue, cleavage of annexin II at the Lys307
residue by pln-like serine protease activity may expose a new
plg/pln binding site. Further studies with purified proteins have
demonstrated enhanced tPA-mediated plg activation in the
presence of annexin II monomer [59], again suggesting that
plg can bind to annexin II directly. However, proteolytically
processed annexin II has not been shown to exist either in vitro
or in vivo and denatured protein has been demonstrated to
stimulate pln formation non-specifically [60].
Surface plasmon resonance studies have demonstrated that
only AIIt or isolated p11 subunit (S100A10) is able to bind
tPA, plg, and pln with moderate affinity, whereas annexin II
subunit is able to bind only pln [60,61]. P11 expression is reg-
ulated by annexin II via a post-translational mechanism in vari-
ous epithelial cell lines and it has been suggested that plgPage 8 of 11
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p11 subunit [61-63]. We observed pln-independent
upregulation of the p11 subunit after PMA stimulation (Figure
2), associated with an increase in plg binding. Our confocal
microscopy data showed a distinct redistribution of annexin II,
and a proportion co-localised with plg and uPA/uPAR in PMA-
stimulated cells (Figure 3). Because p11 expression is
increased by PMA stimulation and has been shown to co-
localise with uPAR [60], it is possible that the pln-independent
increase in plg binding may be partially mediated by the
increase in p11. However, the overall amount of p11 was
small, even after PMA stimulation, and we could not detect
p11 by confocal microscopy. Therefore, p11 may account for
only a very small proportion of plg binding in these cells. Thus,
the presence of both protease-dependent and -independent
plg receptors on modified MCF-7 and MDA-MB-231 cells
serves to indicate that both types of receptor contribute to the
total lysine-dependent plg-binding capacity on invasive cells.
This reflects the increased suite of both uPA-localised and
non-co-localised plg-binding sites on more malignant cells
such as MDA-MB-231 [28], which the PMA-stimulated and
uPA-treated MCF-7 cells mimicked.
The invasive capacity of breast cancer cells may be linked to
the presence of significant levels of active uPA, which in con-
cert with even a moderate amount of bound plg can generate
large amounts of pln at the cell surface through a positive feed-
back mechanism. Mounting evidence points to uPA as an inte-
gral facilitator of breast cancer progression. Recent studies
have indicated that uPA deficiency in a breast cancer mouse
model significantly reduces lung and lymph node metastases
[64], and recent findings by our group indicate that targeting
of uPA (of either tumour or stromal cell origin) with a radiola-
belled ligand significantly retards the growth of MDA-MB-231
xenografts in nude mice [65]. These studies and others indi-
cate the importance of targeting uPA in anti-invasive tumour
strategies.
Conclusion
This study characterises plg binding and activation at the
breast cancer cell surface using techniques that exclude arti-
facts derived from intracellular proteins, contributions from
non-viable cells, and the C-terminal lysine from the uPA A-
chain. We show for the first time that several mechanisms reg-
ulate breast cancer cell plg binding, including direct binding of
plg to uPA/pro-uPA, expression of various plg binding pro-
teins, and pln-mediated generation of plg-binding sites
through limited proteolysis of cell-surface proteins. Critically,
cells with increased uPA and a moderate increase in plg bind-
ing displayed dramatic increases in pln activity. This effect was
not observed in MCF-7 cells with moderate plg binding alone
but was observed in MDA-MB-231 cells, which have naturally
high levels of uPA, pln generation, and invasive capacity. Our
data thus support the model that increased uPA expression at
the cell surface substantially increases pln generation, and
therefore invasive potential, via a positive feedback mecha-
nism. These results also strengthen the evidence implicating
uPA as a strong therapeutic target for the treatment of meta-
static breast cancer.
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